NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NURO opened at $4.35 on Wednesday. The company’s 50 day moving average price is $4.23 and its 200 day moving average price is $4.09. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The company has a market capitalization of $8.93 million, a PE ratio of -0.95 and a beta of 2.15.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC acquired a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned approximately 0.57% of NeuroMetrix as of its most recent filing with the Securities & Exchange Commission. 19.40% of the stock is owned by hedge funds and other institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.